ArticleThe Journal of infectious diseases2026
PvGAP: Development of a Globally Applicable, Highly Multiplexed Microhaplotype Amplicon Panel for Plasmodium vivax.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Spatiotemporal differentiation of Plasmodium vivax populations in the western Greater Mekong Subregion using a 22-SNP barcode.PLoS neglected tropical diseases · 2026Article
- UnderstandingiScience · 2026Article
- PvGTSeq and PvCRiSP: Two amplicon-based targeted sequencing panels for Plasmodium vivax.PLoS neglected tropical diseases · 2026Article
- UnderstandingmedRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
backgroundPlasmodium vivax malaria research has yet to fully benefit from advances in genomic surveillance that have revolutionized P. falciparum epidemiology. Closing this gap will enable monitoring the spread of drug resistance, classifying infections as local or imported, and distinguishing reinfection, recrudescence, and relapse. To achieve these objectives, microhaplotype marker panels that allow powerful genotyping of polyclonal infections are needed.
methodsWe designed a globally applicable amplicon panel for P. vivax (PvGAP), selecting targets based on both genetic diversity and distance to maximize discriminatory capability between geographic regions. We evaluated this panel with field samples from Ethiopia and in silico using whole genomes from the MalariaGEN Pv4 database.
resultsPvGAP has 80 high-diversity targets suitable for population genomics and 8 targets of epidemiological interest, such as putative markers of drug resistance. We demonstrate robust amplification with field data and competitive accuracy for relatedness inference in 3 disparate geographic regions.
conclusionsPvGAP joins existing P. vivax panels as a cost-effective and practical option for genomic epidemiology of this neglected disease. It will support drug resistance surveillance and discrimination of local and imported cases, and it may aid in separating reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs of National Malaria Control Programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.